The Robo Global Healthcare Technology and Innovation ETF seeks to track the ROBO Global Healthcare Technology and Innovation Index, a proprietary benchmark of companies that derive a meaningful portion of revenue from healthcare technology and possess the potential to grow through innovation and product adoption. The fund is passively managed and holds approximately 65 securities, with the top ten positions representing roughly 22% of net assets — a relatively diversified profile for a thematic vehicle.
Largest holdings include Moderna (MRNA), Twist Bioscience (TWST), GRAIL (GRAL), Natera (NTRA), Guardant Health (GH), Arrowhead Pharmaceuticals (ARWR), Axogen (AXGN), CareDx (CDNA), Intuitive Surgical (ISRG), Tempus AI (TEM), Thermo Fisher Scientific (TMO), and Illumina (ILMN). Sector exposure is nearly all healthcare (about 98%), with a residual sliver in technology. The fund carries a net expense ratio of 0.68% and roughly $112 million in assets under management (AUM), classifying it as a smaller, niche thematic product. Its mid-cap growth orientation means the fund tends to be more volatile than broad-market healthcare benchmarks. I also checked this using Tickeron’s AI Screener to see how the holdings align with broader industry trends.
The healthcare technology and innovation universe sits at the intersection of two powerful, but sometimes conflicting, forces: secular demand for precision medicine, genomics, and digital diagnostics on one side, and cyclical sensitivity to interest rates and capital availability on the other. Many constituents — particularly in genomics, molecular diagnostics, and early-stage medical devices — are not yet consistently profitable and rely on longer-dated revenue streams, making their valuations especially responsive to changes in discount rates.
The broader environment has been defined by persistent questions around monetary policy, inflation, and the cost of capital. When yields rise or risk appetite cools, high-multiple growth names typically underperform even when their underlying businesses are executing well; conversely, periods of easing or improving sentiment tend to lift the same cohort disproportionately. Structural growth drivers — an aging population, rising genomic-data volumes, and expanding adoption of artificial intelligence (AI) in drug discovery and diagnostics — continue to underpin long-term demand for the fund's exposure.
HTEC has exhibited meaningful volatility in recent months. After a strong autumn advance that carried shares toward a multi-month high near $47 in early November, the fund reversed course and gave back much of those gains. Over the trailing 30 days, the fund declined roughly 7% to 8%, while the trailing three-month period shows a modest net decline of about 3% to 4%.
The pattern is consistent with a rate-sensitive, growth-oriented basket responding to shifting investor sentiment rather than a deterioration in the fundamentals of most holdings. Several portfolio names have posted substantial gains over the past year — notably diagnostics and genomics franchises such as CareDx (CDNA), Twist Bioscience (TWST), and Natera (NTRA) — reflecting renewed enthusiasm for liquid biopsy, next-generation sequencing, and personalized medicine. At the same time, some large-cap device and diagnostics leaders have lagged, illustrating divergence within the theme. Because no single position dominates the portfolio, HTEC's returns are driven more by the collective behavior of the healthcare technology cohort than by any one stock. From what I see, this diversification helps temper single-name risk in a volatile sector.
Looking ahead, several structural factors are likely to shape HTEC's performance. The trajectory of interest rates and inflation expectations will remain central, given the valuation sensitivity of the fund's mid-cap growth holdings. A more accommodative policy stance could support a re-rating of healthcare technology names, while persistently elevated yields would likely keep multiples under pressure.
The earnings and clinical-development cycles of major holdings also matter. Progress in liquid biopsy, next-generation sequencing, gene editing, and AI-assisted drug discovery could act as catalysts, while disappointing trial results or reimbursement decisions represent downside risks. Regulatory developments — including U.S. Food and Drug Administration (FDA) approvals, Medicare coverage decisions, and potential changes to laboratory-testing reimbursement — may affect a wide swath of constituents. Finally, capital flows into thematic healthcare products and competition from lower-cost or more liquid rivals will influence the fund's standing. These dynamics, rather than short-term price swings, are likely to define the fund's path through 2026. I'm watching this closely as rate decisions unfold.
In my own research process, I often turn to Tickeron’s AI-powered platforms to cross-check thematic exposures and identify comparable opportunities. The AI Screener stands out for its ability to filter securities by technical indicators, fundamentals, volatility, and AI signals, which helps surface relevant names within healthcare technology more efficiently than manual reviews. This approach has been useful when evaluating funds like HTEC against peers in genomics or diagnostics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
HTEC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 56 instances where the indicator turned negative. In 50 of the 56 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HTEC as a result. In 77 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
HTEC moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HTEC crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The RSI Indicator entered the oversold zone -- be on the watch for HTEC's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where HTEC advanced for three days, in 265 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
HTEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 212 of 251 cases where HTEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows